Premium
ICOS‐Dependent and ‐Independent Functions of Memory CD4 T Cells in Allograft Rejection
Author(s) -
Zhang Q.W.,
Rabant M.,
Schenk A.,
Valujskikh A.
Publication year - 2008
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2007.02096.x
Subject(s) - cd154 , effector , blockade , immunology , medicine , antibody , blocking antibody , memory t cell , transplantation , microbiology and biotechnology , t cell , cd40 , cancer research , cytotoxic t cell , biology , immune system , receptor , in vitro , biochemistry
Donor‐reactive memory T cells undermine the survival of transplanted organs through multiple pathways. We have previously reported that memory CD4 T cells resist treatment with anti‐CD154 antibody and donor‐specific transfusion (DST/MR1) and promote cardiac allograft rejection via generation of effector CD4 T cells and alloantibody. We hypothesized that the helper functions of memory CD4 T cells are independent of T‐cell costimulation through CD154 but instead are regulated by alternative costimulatory pathways. This study investigated how blocking ICOS/B7RP‐1 interactions affects functions of donor‐reactive memory CD4 T cells. Treatment with blocking anti‐ICOS mAb synergized with DST/MR1 and prolonged mouse cardiac allograft survival despite the presence of donor‐reactive memory CD4 T cells. While blocking ICOS did not diminish the expansion of preexisting memory CD4 T cells or the induction of allospecific effector T cells, it did inhibit recruitment of the activated memory and effector T cells into the graft. In addition, anti‐ICOS mAb treatment in combination with DST/MR1 prevented help provided by memory CD4 T cells for production of donor‐specific IgG antibody. These results demonstrate the potential efficacy of ICOS blockade in sensitized transplant patients and provide the foundation for rational use of ICOS blockade in combination with other graft‐prolonging strategies.